HIGHLIGHTS
SUMMARY
Over the past decades, systemic treatment for advanced renal cell carcinoma (aRCC) has considerably improved along with the development of new pharmacological targets. To date, combination regimens to treat aRCC include ICI/TKI (avelumab + axitinib, pembrolizumab + lenvatinib, nivolumab + cabozantinib and pembrolizumab + axitinib), ICI/anti-VEGF mAb (atezolizumab + bevacizumab) and a combination of two ICI (nivolumab + ipilimumab). In the field of methods for survival analysis, a new artificial_intelligence technique (called the "Shiny method") has been developed and is increasingly used to reconstruct individual patient data from Kaplan-Meier (KM) curves and to generate cross-trial . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.